Serina Therapeutics (SER) Common Equity (2017 - 2025)
Serina Therapeutics (SER) has disclosed Common Equity for 9 consecutive years, with -$37000.0 as the latest value for Q4 2025.
- Quarterly Common Equity fell 107.28% to -$37000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$37000.0 through Dec 2025, down 107.28% year-over-year, with the annual reading at -$37000.0 for FY2025, 107.28% down from the prior year.
- Common Equity hit -$37000.0 in Q4 2025 for Serina Therapeutics, down from $1.6 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $1.6 million in Q2 2025 to a low of -$37.8 million in Q4 2022.
- Historically, Common Equity has averaged -$15.2 million across 5 years, with a median of -$12.6 million in 2021.
- Biggest five-year swings in Common Equity: tumbled 1527.47% in 2021 and later skyrocketed 111.53% in 2025.
- Year by year, Common Equity stood at -$11.9 million in 2021, then plummeted by 218.13% to -$37.8 million in 2022, then grew by 14.52% to -$32.3 million in 2023, then skyrocketed by 101.57% to $508000.0 in 2024, then plummeted by 107.28% to -$37000.0 in 2025.
- Business Quant data shows Common Equity for SER at -$37000.0 in Q4 2025, $1.6 million in Q3 2025, and $1.6 million in Q2 2025.